Fu­sion Phar­ma marks in-house ra­dio­phar­ma man­u­fac­tur­ing suc­cess, de­tails PhII/III tri­al study

Fu­sion Phar­ma­ceu­ti­cals said it has man­u­fac­tured the first clin­i­cal dose of its ra­dio­phar­ma­ceu­ti­cal as­set in-house and has agreed with the FDA on the de­sign of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER